Operator
Good day. Thank you for standing by. Welcome to the Anaptys conference call. [Operator Instructions] Please note that today’s conference may be recorded.
I will now hand the conference over to your speaker host, Dan Faga, President and CEO of Anaptys. Please go ahead, sir.
Daniel Faga
President, CEO & Director
Good afternoon and thank you for joining us today. We are excited to discuss today the further evolution of Anaptys with our intention to separate our biopharma operations from our substantial royalty assets. This separation is designed to maximize value by creating 2 companies each with different business objectives and opportunities.
After my prepared remarks, our CFO, Dennis Mulroy and I will be available to take your questions. This presentation contains forward-looking statements. Please refer to our SEC filings for further details.
For the past 20 years, Anaptys has been known for generating best-in-class antibodies. Jemperli and imsidolimab are 2 previous successes discovered by Anaptys. Both are realizing value through our financial collaborations as well as have positively impacted patient lives.
Jemperli’s commercial uptake over the last 12 months, combined with its anticipated future growth is nothing but impressive. This results in an outsized tiered royalty stack payable from GSK that flows through to Anaptys. We are equally excited about Anaptys’ proprietary development stage portfolio of immune cell
#AnaptysBio #Special #Call